Ontology highlight
ABSTRACT: Importance
Intravitreous injections of antivascular endothelial growth factor agents are effective for treating diabetic macular edema (DME) involving the center of the macula (center-involved DME [CI-DME]) with visual acuity impairment (20/32 or worse). The best approach to treating patients with CI-DME and good visual acuity (20/25 or better) is unknown.Objective
To compare vision loss at 2 years among eyes initially managed with aflibercept, laser photocoagulation, or observation.Design, setting, and participants
Randomized clinical trial conducted at 91 US and Canadian sites among 702 adults with type 1 or type 2 diabetes. Participants had 1 study eye with CI-DME and visual acuity of 20/25 or better. The first participant was randomized on November 8, 2013, and
SUBMITTER: Baker CW
PROVIDER: S-EPMC6537845 | biostudies-literature | 2019 May
REPOSITORIES: biostudies-literature